iRhythm Technologies is building momentum in 2023 with the development of new Zio electrocardiogram monitoring devices, clinical trial results, and expansion into new markets.
Cardio Conversations: iRhythm Prepares To Deliver ‘Standard-Of-Care’ Cardiac Monitoring
Quentin Blackford, CEO of iRhythm, talked to Medtech Insight about his company’s plans to bring its Zio long-term cardiac monitoring platform to more patients by building its evidence base and marketing in more countries outside the US.
